Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Tonix Pharma (TNXP) is now available.
Tonix Pharmaceuticals is gearing up for a major milestone with the help of EVERSANA, as it prepares to launch its innovative fibromyalgia treatment, Tonmya™, in the U.S. market. The company is on track to submit a New Drug Application to the FDA in the latter half of 2024 and is proactively arranging a pre-NDA meeting with the agency. Investors and market watchers are cautioned to consider the usual risks and uncertainties of such forward-looking statements, although the anticipation for Tonmya’s potential impact on the fibromyalgia medication market is building.
See more data about TNXP stock on TipRanks’ Stock Analysis page.